Scientific Research News
Stay updated on research with press releases highlighting industry news, trends, and innovations driving scientific studies and academic research. Explore opportunities in research methodologies, peer-reviewed publications, and collaborative projects.
Feb 2, 2026 at 12:28 AM
PF NATURE Advances Global Reach of Innovative K-Beauty OEM and ODM Solutions
OSONG, South Korea--(BUSINESS WIRE)--PF NATURE, a South Korea-based cosmetics OEM/ODM company, is broadening its science-backed K-Beauty solutions to the global market....
Feb 2, 2026 at 12:00 AM
FUJIFILM Dimatix Launches the DMP-2850 S Materials Printer Designed for Researchers and Universities
LEBANON, N.H.--(BUSINESS WIRE)--FUJIFILM Dimatix, Inc., a leading global manufacturer and supplier of piezoelectric, drop-on-demand industrial inkjet printheads, announced the launch of its new Dimatix Material Printer DMP-2850 S (DMP-2850 S), a benchtop materials deposition system designed for micro-precision jetting for a variety of functional fluids for virtually any surface, including plastic, glass, ceramics, and silicon, as well as flexible substrates from membranes, gels, and thin films...
Jan 30, 2026 at 12:00 PM
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
SAN DIEGO--(BUSINESS WIRE)--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program...
Jan 30, 2026 at 11:44 AM
CD137 Targeted Therapy Research Report 2026-2030: Market Opportunities, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Highlights: First CD137 Targeted Therapy Commercial Launch Expected by 2030 Insight on CD137 Targeted Therapies in Clinical Trials: > 90 Therapies CD137 Targeted Therapies Clinical Trials Insight by Company, Country, Indication and Phase Highest Clinical Trials P...
Jan 30, 2026 at 11:37 AM
MYC Targeting Therapies Market Research Report 2026-2030, Profiles of Genetic Leap, Curigin, IDP Pharma, Incurix, Omega, Panavance, Peptomyc, Suzhou Kintor, Wayfinder Biosciences, WebenPharma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: First MYC Targeting Therapy Approval Expected by 2030 Global MYC Targeting Therapies Market Opportunity Outlook Comprehensive Insight on MYC Targeting Therapies in Clinical Trials: > 10 Therapies MYC Targeting Drugs Clinical Trials Insig...
Jan 30, 2026 at 9:39 AM
GLP-1 Analogues Market Research 2025: Increasing Diabetes and Obesity Rates and a Strong R&D Pipeline Support Market Expansion - Forecast to 2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "GLP-1 Analogues Market" report has been added to ResearchAndMarkets.com's offering. This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025-2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP...
Jan 30, 2026 at 8:00 AM
Coya Therapeutics Announces $11.1 Million Private Placement
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte...
Jan 30, 2026 at 8:00 AM
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i...
Jan 30, 2026 at 2:00 AM
Merz Therapeutics Appoints Dan Staner as President, Region Europe
FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerati...
Jan 29, 2026 at 4:47 PM
St. Jude Children’s Research Hospital Again Named a Top U.S. Brand by YouGov
MEMPHIS, Tenn.--(BUSINESS WIRE)--St. Jude Children’s Research Hospital® has been recognized for the second year in a row as one of the top brands in the United States. According to YouGov’s Best Brand Rankings 2026 report, St. Jude rose one place to No. 6, remaining the only nonprofit among America’s top 10 brands and the brand with the highest reputation score. YouGov’s annual report evaluates brands through more than one million public opinion surveys measuring six key indicators of brand hea...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.